Business View Magazine - May 2016 89
integrated service partner to the pharmaceutical in-
dustry, a string of acquisitions ensued.
“In 2012, in order to forward integrate with broader
and more complex range in drug products, we identi-
fied ‘sterile fillings’ as an attractive business segment.
Thus, we acquired a company in Irvine CA, called AMP
with highly-sophisticated, sterile injectable capabili-
ties and steriles for small scale product demand (Alli-
ance Medical Products),” says Späne. Then in 2014,
Siegfried bought the German company, Hameln Phar-
maceuticals GmbH and Hameln RDS Gmbh, which
created a more powerful network in the drug product,
pharma space for Siegfried, as Hameln the sterile in-
jectable offering provided the larger scale demand in-
jectable solution. Having both companies on board,
afforded Siegfried the ability to cover the entire inject-
able customer demand platform.
During the same year as the Hameln integration, Sieg-
fried wanted to backward integrate as well. This would
bring about major reduction in the factor costs for
chemical production and allow the company to main-
tain a competitive edge in the drug substance phar-
maceutical space. The core element to achieve this
milestone was to add a brand new site in a lower cost-
to-manufacture country such as China. Siegfried pur-
chased land within a key industrial campus of China,
Nantong, broke ground, and began building a state-of-
the-art, fully cGMP facility. “We built our own site from
ground up, in Nantong, to offer a lower cost option to
support the emerging pharma market. Nantong is
closely linked to various projects in our Zofingen plant
that will commence operations late in 2015 and 2016
that have similar technical designs to the Nantong
plant, making it easier for our company to transfer
products between both sites.” Spane says.
There was, however, still one more major ac-
quisition left for Siegfried to make within the
“Transform” strategy. The Siegfried Company,
this past fall, acquired significant segments of
BASF’s fine chemicals business, purchasing
part of their API and customer manufacturing
pharmaceutical supply businesses, inherit-
ing three production units: Minden, Germany;
Saint-Vulbas, France; and Evionnaz, Switzer-
land. The acquisition represented the final,
major step in Siegfried’s transformation pro-
cess implemented over the last five years. The
company now has nine sites spanning both
the Eastern and Western hemispheres of the globe.
“The final transform milestone of BASF gives us the
leverage, critical size, and site mass now for us to be
a very strategic CDMO partner to our big pharma cli-
ents,” says Späne.
Today, Siegfried serves a large, diversified customer
landscape with clients ranging from mid-sized and
emerging pharma company sizes, to the more gross
pharmaceutical partners across the entire pharma
sector. Siegfried develops and manufactures APIs for
the research-based pharmaceutical industry, as well
as providing development and production services for
drugs in finished dosage forms. Siegfried has many
relationships with suppliers that support them.
